Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer McDonald

Obstetrics & Gynecology Chesterfield, MO Doctor of Osteopathy

NPI 1376641886 CMS profile 108164

111 Saint Lukes Center Dr Ste 44, Chesterfield, MO 63017

Open in the dashboard

General payments

$7,070

279 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer McDonald of Chesterfield, MO is reported in the CMS Open Payments database as having received $7,070 across 279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $645 36
2024 General $722 39
2023 General $1,018 45
2022 General $836 52
2021 General $927 51
2020 General $490 30
2019 General $2,431 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer McDonald
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Jennifer McDonald were reported at $645. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Jennifer McDonald Obstetrics & Gynecology median Middle half National median
2019 $2,431 $172 $62–$391 $163
2020 $490 $94 $36–$222 $114
2021 $927 $136 $42–$369 $132
2022 $836 $160 $50–$433 $149
2023 $1,018 $169 $56–$423 $160
2024 $722 $152 $50–$371 $164
2025 $645 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Minerva Surgical, Inc $2,034 4 payments
  2. AbbVie, Inc. $1,058 55 payments
  3. Amgen Inc. $411 24 payments
  4. Mayne Pharma Inc. $398 25 payments
  5. Sage Therapeutics, Inc. $313 18 payments
  6. TherapeuticsMD, Inc. $282 19 payments
  7. Evofem Biosciences, Inc. $259 16 payments
  8. Astellas Pharma US Inc $258 13 payments
  9. Medtronic, Inc. $247 3 payments
  10. Exeltis, USA Inc. $200 11 payments
  11. Other $1,610 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,158 275 payments
  2. Consulting Fee $1,500 1 payment
  3. Travel and Lodging $296 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100 1 payment
  5. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. Endometrial Ablation System (Device) $1,896 3 payments
  2. Prolia $411 24 payments
  3. EVENITY $398 23 payments
  4. ORILISSA Womens Health $303 19 payments
  5. Orilissa Endocrinology $302 7 payments
  6. ZURZUVAE $239 14 payments
  7. Veozah $223 11 payments
  8. INTERSTIM $210 1 payment
  9. Twirla $195 12 payments
  10. LILETTA $193 14 payments
  11. Other $3,420 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

506

Median for Obstetrics & Gynecology: 65

Drug cost

$14,054

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

50.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Progesterone Progesterone, Micronized Brand 192 $6,346
Estradiol (Once Weekly) Estradiol Brand 13 $1,546
Estradiol Generic 47 $1,471
Armour Thyroid Thyroid,pork Brand 15 $1,272
Tolterodine Tartrate Er Tolterodine Tartrate Brand 11 $891
Spironolactone Generic 56 $706
Valacyclovir Valacyclovir Hcl Brand 14 $429
Np Thyroid Thyroid,pork Brand 11 $415
Norethindrone Acetate Generic 14 $354
Minoxidil Generic 20 $243

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$8,624

Medicare's payments for the services billed

Medicare patients

75

Average age 70

Services billed

122

75 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 48%
Arthritis 36%
Depression 21%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $81
$81 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $36
$36 — —
SLYND
  • Exeltis, USA Inc. $32
$32 — —
CALDOLOR
  • Cumberland Pharmaceuticals, Inc. $23
$23 — —
ABRYSVO
  • PFIZER INC. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record